CHCWM – Cancer & Hematology Centers of West Michigan

JTX 8064 (Jounce, Inc)

Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 Inhibitor Monoclonal Antibody JTX-8064, as Monotherapy & in Combination with a Programmed Cell Death Receptor-1 Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies